Business Wire

ISC High Performance 2022: Liqid Introduces EMEA Attendees to Composable Disaggregated Infrastructure for a More Flexible, Sustainable Data Center

30.5.2022 09:30:00 EEST | Business Wire | Press release

Share

Liqid, the world’s leading software company delivering data center composability, announced today it is taking part in ISC High Performance 2022 (booth #B211), providing live demonstrations of the company’s Liqid Matrix™ composable disaggregated infrastructure (CDI) software. Dynamic infrastructure orchestration from Liqid delivers improved IT performance and agility for the most demanding next-gen applications such as artificial intelligence and machine learning (AI+ML), edge computing deployments, high-performance computing, and virtualization. Increased efficiency helps minimize the data center footprint, delivering software-defined ability to share resources no matter where they physically reside, making Liqid solutions fundamental to a more sustainable data center ecosystem. Available today for customers in the Europe, Middle East, & Africa (EMEA) region, solutions based on Liqid Matrix CDI software deliver architectural flexibility and efficiency to maximize time-to-value for high-value applications across industry verticals.

“AI applications, edge data center deployments reading multiple streams of sensor data, HPC-driven genomic research, and even more traditional software deployments like virtualization are taxing traditional data center infrastructures, increasingly making them neither practical nor sustainable,” said Paul Silver, Vice President and General Manager, EMEA, Liqid. “We’re excited to be able to bring our composable solutions to ISC High Performance attendees and the wider EMEA market to help better address the sea changes taking place in the data center ecosystems.”

Liqid Matrix software enables IT users to configure bare-metal servers in seconds. With Liqid Matrix, independent resource pools are orchestrated on-demand to instantly address the requirements of the specific workload. Once the workload is complete, resources are released back into the pool for use by other applications. This eliminates the need for costly overprovisioning of infrastructure, reduces power and cooling requirements, and enables the most efficient and sustainable data center architectures.

Liqid offers EMEA customers a cost-effective way to disaggregate and pool data center resources at large scale via software, across all industry-standard fabrics, for dynamically configurable, bare-metal servers. With composable disaggregated infrastructure solutions from Liqid, IT users can:

  • Accelerate Time-to-Value: Dynamically configure servers in seconds to meet exacting workload requirements. Create configurations that aggregate the power of dozens of GPUs and other accelerators as required.
  • Improve IT Agility: Scale resources like compute, networking, NVMe storage, GPU, FPGA, and storage-class memory beyond a server’s physical limitations, across all industry-standard fabrics, with just a couple of clicks; when data center devices are no longer needed, they are released back to the pool to be used by other applications. Leverage Liqid Command Center’s RESTful API and integrations with popular tools like Ansible to automate the provisioning of bare‐metal resources.
  • Increase Efficiency: Only purchase resources when they’re needed. Extend the life cycle of existing IT server investments. Better manage costs associated with data center footprint with greater infrastructure utilization.

“Liqid is a company that offers a flexible, software-defined infrastructure designed to optimize the access and usage of high-value IT components. Liqid has worked to create what it called ‘composable disaggregated infrastructure’ that frees IT users from vendor lock-in and traditional purchasing cycles, enabling them to build a living data center architecture that changes to meet their business needs and scales as required,” wrote senior analyst Scott Sinclair and senior research analyst Moya Keane of Enterprise Strategy Group (ESG), a division of TechTarget, in a recent ESG Showcase. “A composable infrastructure provides significant improvements to performance, architectural optimization, hardware utilization issues, and, importantly, footprint efficiency—basically eliminating the urge to overprovision.”

To download ESG’s “Why IT Must Prioritize Sustainability,” go here. Schedule an appointment with an expert on solutions based on Liqid Matrix CDI software and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.

About Liqid

Liqid’s composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Robert Brumfield
Sr. Director, Global Communications
Liqid
917 224 7769
brumfield.bob@liqid.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye